Successful encorafenib desensitization in a patient with recurrent metastatic melanoma

Type I hypersensitivity reactions (HSR) to dabrafenib are rare but have been previously described. We present a case where a 72-year-old woman with recurrent, metastatic BRAF-mutated melanoma developed a type I HSR to dabrafenib. We, therefore, developed a desensitization protocol with encorafenib, a similar class agent, to allow the patient to continue with treatment. Patients with a history of HSR to dabrafenib may be considered for encorafenib desensitization when other therapeutic options are limited.

Automated summary

Type I hypersensitivity reactions to dabrafenib are rare but can occur in patients with BRAF-mutated melanoma. In this case, a desensitization protocol with encorafenib was successful in allowing the patient to continue treatment, suggesting it as a potential option for patients with limited therapeutic alternatives.